Scores of anecdotal feedback over the years could lead many to conclude that cannabis is safe and effective for recreational and many medical uses.
But, the lack of lab data halts any determination made by governments and departments such as the U.S. Food and Drug Administration (FDA).
Proving the safety and efficacy of the plant remains difficult. Factors such as federal prohibition, cannabis use and the plant's makeup all play a part. The nascent space is doing its part to provide the federal government and consumers with assurances as best it can.
Sources say the companies attempting to carve out their place in the market must provide proof to consumers through studies and protocols to verify the safety of cannabis and the brand producing them.
Barriers Prevent Cannabis From Proving Its Safety Or Efficacy To FDA: While most of the public may be convinced of cannabis, the FDA process has only approved four medications so far: The CBD-derived epilepsy medication Epidiolex; Marinol, a dronabinol-based synthetic cannabis-derived nausea medication; Syndros, a dronabinol-based liquid synthetic cannabinoid used for nausea and appetite loss; and Cesamet, a nabilone-based synthetic used to treat extreme nausea and vomiting.
Dr. Jordan Tishler, CEO of inhaleMD and president of the Association of Cannabis Specialists, said the major obstacle in the way of wider-scale approval is that the plant's many chemicals appear to work together to produce its expected result. This effect is …